LY3451838 / Eli Lilly - LARVOL DELTA

Is PACAP the next big thing in migraine therapy? (PubMed, Cephalalgia) - No abstract available

Journal • CNS Disorders • Migraine • Pain • ADCYAP1

Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine. (PubMed, Cephalalgia) - P1, P2 | "However, the difference observed between LY3451838 and placebo among CM patients is similar to the statistically significant difference reported in the recent HOPE trial, which primarily consisted of CM patients. Further clinical research with larger sample sizes is needed to inform on the utility of blocking PACAP in various migraine populations.Trial RegistrationClinicalTrials.gov: NCT03692949 (phase 1); NCT04498910 (phase 2)."

Clinical • Journal • P1 data • P2 data • Preclinical • B Cell Lymphoma • CNS Disorders • Hematological Malignancies • Lymphoma • Migraine • Non-Hodgkin’s Lymphoma • Oncology • Pain • ADCYAP1

A Study of LY3451838 in Participants With Migraine (clinicaltrials.gov) - P2 | N=38 | Completed | Sponsor: Eli Lilly and Company | Recruiting ➔ Completed | N=120 ➔ 38

Enrollment change • Trial completion • CNS Disorders • Migraine

A Study of LY3451838 in Participants With Migraine (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: Eli Lilly and Company; Trial completion date: Nov 2021 ➔ Sep 2022; Trial primary completion date: Nov 2021 ➔ Sep 2022

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Migraine

A Study of LY3451838 in Participants With Migraine (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • CNS Disorders • Migraine

A Study of LY3451838 in Participants With Migraine (clinicaltrials.gov) - P2; N=120; Not yet recruiting; Sponsor: Eli Lilly and Company; Trial primary completion date: Dec 2020 ➔ Nov 2021

Clinical • Trial primary completion date • CNS Disorders • Migraine

A Study of LY3451838 in Participants With Migraine (clinicaltrials.gov) - P2; N=120; Not yet recruiting; Sponsor: Eli Lilly and Company

Clinical • New P2 trial • CNS Disorders • Migraine

A Study of LY3451838 in Healthy Participants (clinicaltrials.gov) - P1; N=53; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed; N=80 ➔ 53

Clinical • Enrollment change • Trial completion